NEW YORK (TheStreet) -- Barclays downgraded C.R. Bard (BCR) to "equal weight" from "overweight." The firm noted pressure on the company due to its exposure to the peripheral vascular space affected by the Medtronic (MDT) deal with Covidien (COV).
The stock closed at $137.74 on Tuesday.
Must Read: Warren Buffett's 25 Favorite Stocks